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Abstract
Increasingly older adults are traveling to international destinations with malaria as a present risk.

from malaria. The role of health care providers in selecting an appropriate medication for
chemoprophylaxis or treatment of malaria in adults becomes more difficult as older adults
undergo physiologic changes that alter the pharmacokinetic and pharmacodynamic nature of
medications potentially causing increased drug interactions, adverse events, and altered drug
action. A comprehensive literature search from 1970 to present, with a focus on the last 10
years, was conducted on drug interactions, pharmacokinetic and pharmacodynamic effects on
antimalarials in adults. It was determined that due to pharmacodynamic and pharmacokinetic
changes in older adults, especially renal and cardiovascular, special attention should be given to
this population of travelers in order to minimize the likelihood of adverse events or altered drug
efficacy. Antimalarial-disease interactions in older adults can occur more often due to QT
prolongation, exacerbation of hypoglycemia, decreased renal elimination, and decreased hepatic
metabolism. Older antimalarials have well documented drug-drug interactions. Tafenoquine, a
new antimalarial, requires G6PD screening like primaquine and monitoring of new potential
drug interaction with MATE1 and OCT2 substrates. While drug-drug interactions in older
travelers may occur more often as a result of poly-pharmacy, data does not indicate adverse
reactions or decreased drug efficacy is greater compared with younger adults. Overall, with the
exception of recently approved tafenoquine, much is known about antimalarial drug and disease
interactions, but new drugs are always being approved, requiring travel health providers to
understand the pharmacokinetics and pharmacodynamics of antimalarial drugs to predict the
impact on safety and efficacy in travelers. This guide provides travel health providers with
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valuable insights on potential outcomes associated with drug interactions in adults and
recommended monitoring or drug regimen modification.

mefloquine, chloroquine, artemisinins, artesunate, artemether, hepatic enzyme induction, QT
prolongation
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Introduction

Those over 60 years of age represent about 8% of ill returned travelers, but of those, more have
severe disease compared to younger travelers.2 In 2016, the U.S. Centers for Disease Control
and Prevention (CDC) received 2,078 reports of imported malaria, the most since 1972.3 While
the percentage of adults 65 years and older only accounted for 6.3% of those with malaria in this
report, 19.2% of them developed severe malaria, which included cerebral and kidney damage as
well as acute respiratory distress syndrome. Studies in Asia and Europe indicate the incidence of
hyperparasitemia and renal insufficiency increase with age, and the risk of death due to
falciparum malaria increases by 85% per decade of life.4, 5 It has been suggested that the
increased susceptibility to severe malaria might be due to a waning immune system or
atherosclerosis, which is more common in older adults.6 Also, older adults undergo physiologic
changes that compromise the pharmacokinetic and pharmacodynamic nature of the medications
they take, leading to increased drug-drug interactions, adverse events, and altered drug action.7
An analysis of TravEpiNet, a large CDC funded pre-travel project, revealed that of potential
drug-drug interactions, 61% occurred in those over 50 years of age and 41% had at least three
comorbid conditions.8 Since 1988, the number of medications taken by adults 65 years and older
have doubled, and those taking 5 or more medications have tripled.9 A recent systematic review
underscored the need to not only consider the implications of pharmacologic changes associated
with aging, but also that older adults are more likely to forego insect protection and may be less
likely to adhere to antimalarial regimens.10 This review aims to address the drug-drug, drug-
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disease, physiologic and pharmacokinetic changes in older adults that are critical to protecting
this vulnerable population against malaria and its severe complications.

A comprehensive literature search from 1970 – present, with a focus on the last 10 years,
was conducted to identify relevant studies and background information on the use of
antimalarials in older adult travelers. Database searches were conducted in PubMed, Cochrane
Database of Systematic Reviews, WHO Global Index Medicus, Web of Science, and CINAHL.
Searches were conducted using the keywords and mesh terms: aged, antimalarials, artemisinin,
atovaquone-proguanil, chemoprophylaxis, chloroquine, doxycycline, drug-drug interactions,
malaria, mefloquine, primaquine, tafenoquine, and travel. International trade names for the
antimalarials were searched on drugs.com and through the monographs Index Nominum and
Martindale: the Complete Drug Reference. Search results were also limited to English-language
studies and humans. References of identified articles were reviewed to identify any additional
studies not found in the initial search. The search was conducted by four independent authors.
After thorough discussion among the authors, articles were selected for inclusion into this
manuscript based on their relevance to the topic as well as detailed and complete results.
Results
Pharmacokinetic and Pharmacodynamic Changes
Due to physiological changes associated with aging, the pharmaceutical care of older
adults differs from younger adults. Changes in important organ systems like the renal and
cardiovascular affect the pharmacokinetics (i.e., drug absorption, distribution, metabolism, and
excretion) and pharmacodynamics (i.e., effect of drug at the target site) of medications.11, 12 For
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example, with increased age there is a relative decrease in total body water, lean muscle mass,
and increase in percentage of body fat.11-13 These changes will alter the usual volume of

metabolism of drugs in older adults can be reduced by up to 30% while renal excretion can be
decreased by 50%.14 Drug clearance by the liver depends on perfusion and extraction ratio.12
Since extraction ratio is dependent on the metabolizing capacity of the liver, a decrease in
hepatic drug metabolism may also reduce hepatic drug clearance.12
Pharmacodynamic changes in older adults usually results in increased or decreased drug
sensitivity, depending upon the class of medication.12 Reasons for pharmacodynamic changes in
older adults are less well understood but are most pronounced for cardiovascular and central
nervous system effects of various drugs.11, 15
Changes in older adults are important considerations when selecting an antimalarial
medication for prophylaxis or treatment. Some common adverse events with antimalarial agents
that warrant more consideration in older adults are a risk for QT prolongation and hypoglycemia.
Many antimalarial drugs can cause QT prolongation and in older adults there is increased risk of
this due to pre-existing cardiovascular disease, use of concurrent QT-prolonging drugs and agerelated increases in QT interval.11, 15, 16 Some antimalarial drugs can cause insulin production
resulting in increased risk of hypoglycemia especially in older adults on concurrent anti-diabetic
medications.17, 18 There is also strong concern for drug-drug and drug-disease interactions in
older adults due to increased medication use and comorbidities with age.11

Atovaquone-proguanil
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Atovaquone-proguanil is indicated for prophylaxis and treatment of uncomplicated
malaria in adults and children weighing 5 kg or greater.

Atovaquone and proguanil are both active against all stages of the malaria parasite life
cycle.19, 20 Atovaquone is a hydroxynaphthoquinone and is a ubiquinone analogue that disrupts
the cytochrome electron transport system and hinders the transport of several parasite enzymes
which lowers the mitochondrial membrane potential.20, 21 Proguanil must be converted into the
active metabolite, cycloguanil, which inhibits dihydrofolate reductase in the Plasmodium species
leading to the inhibition of deoxythymidylate synthesis.22
Atovaquone is a lipophilic compound, and thus, it is poorly absorbed from the GI tract. In
older adults, lipophilic drugs may have a larger volume of distribution with a longer half-life
resulting in greater systemic exposure and an increased risk for adverse effects.14 Proguanil is
readily absorbed from the GI tract. To increase absorption, atovaquone-proguanil should be
taken with food, preferably a fatty meal, at the same time every day, which increases the
bioavailability to 21-23%.23, 24 Atovaquone has a half-life of about 2-3 days in adults due to
enterohepatic recycling.23 While it is highly protein bound (>99%), atovaquone does not seem to
displace other highly protein-bound drugs in vitro.23 Proguanil is 75% protein bound and it has a
half-life of 12-21 hours.23 According to the manufacturer, single-dose pharmacokinetics of
atovaquone, proguanil, and cycloguanil were studied in 13 elderly subjects (65-79 years of age)
and compared to 13 younger subjects (30-45 years of age).23 Systemic exposure, or area under
the curve, of cycloguanil was higher in the older adult population (point estimate 2.36, 95% CI
1.70 to 3.28). The Tmax and elimination half-life were longer in the older adult population when
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compared to the younger population (8 hours vs 4 hours and 14.9 hours vs 8.3 hours,
respectively).23, 25 When using atovaquone-proguanil in older adults the possibility of higher

may be greater.
Undetectable amounts (<0.6%) of atovaquone pass through the kidney.26 About 40-60%
of proguanil is excreted renally.23, 25 In patients with severe renal impairment there is a risk for
pancytopenia which can result from proguanil accumulation.27 Thus, for patients with CrCl <30
mL/min prophylaxis with atovaquone-proguanil is contraindicated and treatment of malaria with
atovaquone-proguanil should only be used if the benefits outweigh the risks. These are important
considerations in older adults as they are more likely to have renal impairment than younger
individuals.12
Atovaquone is almost primarily excreted via the liver.26 It has been postulated that some
of atovaquone also undergoes enterohepatic recirculation.26 Proguanil undergoes hepatic
metabolism via CYP2C19 and CYP3A4 at which time it is converted into cycloguanil.23, 28 There
are currently no dosage adjustment recommendations for atovaquone-proguanil in patients with
mild to moderate hepatic impairment. Studies have not been conducted in patients with severe
hepatic impairment taking atovaquone-proguanil.23

Pharmacodynamic Effects
Although mostly well-tolerated, atovaquone-proguanil may cause gastrointestinal (GI)
disturbances such as abdominal pain, nausea, vomiting, and diarrhea.23 Rarely, allergic reactions,
blood disorders, photosensitivity, rash, increased liver enzymes, hepatitis, and hepatic failure
may occur.23
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Drug-drug Interactions

52%.23, 29 (Table 1) The mechanism of this interaction is not known, but it has been suggested
that the ability of rifamycin to induce hepatic enzymes and drug transporters may be
responsible.26 Certain HIV medications such as efavirenz, lopinavir/ritonavir, and
atazanavir/ritonavir have also been shown to lead to lower plasma concentrations of atovaquone
and proguanil.30, 31 (Table 1) Although not demonstrated, studies have suggested that this may be
due to atovaquone plasma protein displacement of these drugs.26, 30 Similarly, the plasma
concentration of atovaquone may be reduced by 40% when taken with tetracycline and the
bioavailability of atovaquone may be lower if taken with metoclopramide.23 (Table 1) If these
drug interactions cannot be avoided, dosage adjustments and closer monitoring of patients for the
development of malaria is warranted. Atovaquone may increase the plasma concentrations of
zidovudine, by inhibiting its metabolism through glucuronidation, and etravirine and saquinavir,
by interfering with CYP450 mediated metabolism, possibly on the 2C isoenzymes.32, 33
Atovaquone-proguanil may potentiate the anticoagulant effect of warfarin by increasing the free
warfarin concentrations through plasma protein displacement.26, 34-36 (Table 1) Closer monitoring
of the warfarin dose is necessary to avoid excessive bleeding. Proguanil, at twice the dose used
in the adult formulation of atovaquone-proguanil, may decrease the efficacy of the oral typhoid
vaccine due to in vitro antibacterial activity that decreases replication of the vaccine strain in
vivo, which in turn, diminishes vaccine efficacy.37 However, subsequent work in children using
atovaquone-proguanil showed no decrease in the immunogenicity of the oral typhoid vaccine and
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thus the Centers for Disease Control and Prevention state it may be given together or at any
interval.38, 39

For patients with HIV and those patients taking rifampin, rifabutin, or warfarin an
alternative agent should be considered for malaria prophylaxis or treatment. An increase in age
leads to an increase in potential for comorbidities and the need for anticoagulation.40 Thus, older
adults are more likely to be on warfarin therapy and this should be a consideration with
atovaquone-proguanil. INR should be closely monitored at baseline and throughout therapy.
Kidney function should also be evaluated prior to start of therapy.

Doxycycline
Doxycycline is indicated for chemoprophylaxis and treatment of severe or uncomplicated
malaria.

Pharmacologic/Pharmacokinetic Effects
Doxycycline is a broad-spectrum antibiotic. It is synthetically derived from oxytetracycline
which makes it related to tetracycline.19 The dosage for chemoprophylaxis of malaria is 100 mg
once daily, whereas for many other indications, it is given twice daily. Thus, the magnitude of
pharmacodynamic effects for non-malaria dose studies should be interpreted with caution.
Doxcycline has a longer half-life than tetracycline and a better absorption profile.19 As an antimalarial medication, it interrupts the apicoplast function in plasmodium thereby inhibiting
protein synthesis.41, 42 After oral administration, doxycycline is quickly and almost entirely
absorbed.43 Divalent cations, such as calcium in dairy products, and trivalent cations decrease
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doxycycline absorption, but otherwise, doxycycline is not affected by food.44, 45 It does undergo
enterohepatic recirculation which may slow clearance of the medication and it is primarily

of doxycycline was higher in older adults 65-90 years of age (mean 76.3 ±6 years) compared to
younger individuals.46
The clearance of doxycycline is similar in individuals with normal renal function and in
those with renal impairment.47 No dosage modifications are needed for hepatic insufficiency.

Pharmacodynamic
Gastrointestinal
Doxycycline may cause gastric irritation. Doxycycline hyclate has been shown to cause
more gastrointestinal side effects than doxycycline monohydrate and the incidence of esophageal
ulcers is higher with doxycycline hyclate capsules than with tablets.43, 48 Because of this, GI
disturbances such as nausea and abdominal pain commonly occur as well as vomiting and
diarrhea, which are less common.43 To lessen the likelihood of this adverse effect and to avoid
esophagitis, doxycycline should be taken with food, a full glass of water and in an upright
position.49 Dysphagia, esophageal ulceration, dry mouth, glossitis, enterocolitis, and stomatitis
have also been reported.9 While once thought to increase the rate of Clostridium difficile
infection, newer evidence suggests it may decrease the rate.50
Dermatologic
Photosensitivity is a common adverse effect of doxycycline. Patients should avoid
excessive sun exposure while on this medication and ensure the use of sunscreen when going
outdoors. Other adverse effects include inflammatory lesions in the ano-genital region, skin
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reactions, exfoliative dermatitis, and hypersensitivity reactions.19 Case reports mention skinhyperpigmentation, post-inflammatory elastolysis, and tooth discoloration with long-term

Other
Although not reported in patients taking doxycycline for malaria prevention, doxycycline
has rarely been associated with benign intracranial hypertension.43 Hematologic abnormalities
have been reported in rare cases.51

Drug-drug Interactions
Dairy products, such as milk, decrease the absorption of doxycycline due to their calcium
content. Antacids, bismuth subsalicylate, proton pump inhibitors, and oral iron products also
decrease the absorption of doxycycline.52-54 (Table 1) In addition, older adults are at higher risk
for adverse effects with PPIs.55, 56 In a Gallup Survey, 22% of responders who were greater than
50 years old stated they used antacids and other anti-dyspepsia agents two or more times per
week.57 In this same poll, only 9% of the responders younger than 50 admitted to doing the
same.57 Since older adults are more likely to be taking these agents, and many are over the
counter, health care providers should discontinue or seek alternatives to these types of
medications prior to prescribing doxycycline.
Hepatic enzyme inducers such as certain antiepileptic drugs, rifampicin, and chronic
alcohol use may increase the metabolism of doxycycline.58-62 (Table 1) Another major
interaction that has been described in literature is the competitive plasma protein displacement of
methotrexate by doxycycline leading methotrexate toxicity.36 (Table 1) Over anticoagulation can
occur when warfarin and doxycycline are given together through pharmacodynamic inhibition of
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vitamin K dependent coagulation factors, and pharmacokinetic, protein binding displacement,
mechanisms.63 (Table 1)

Anticoagulation
With increasing age, there is an increased likelihood for comorbidities, such as atrial
fibrillation, and the need for anticoagulation and older adults are also at an increased risk for
hemorrhage from anticoagulation therapy.40, 64 Doxycycline should be avoided or the INR needs
to be monitored closely with the concomitant use of warfarin, especially in older adults.
Fungal infections
Due to the suppression of vaginal bacterial flora, doxycycline has been implicated in the
development of candidal vulvovaginitis.43 Individuals predisposed to candidal vulvovaginitis,
such as those with diabetes mellitus, or prior medical history of recurring vulvovaginitis, may
benefit from carrying a course of antifungal treatment on their trip.43, 65 Elevated blood sugars
may predispose patients to candida infections. Older adults are more likely to have diabetes and
thus, they should be counseled regarding the increased risk for candida infections especially if
they will take doxycycline for a prolonged period of time.66
Photosensitivity
As older adults are more likely to have comorbid conditions such as diabetes and hypertension,
they may already be taking certain medications such as thiazide diuretics and sulfonylureas
which may cause photosensitivity.40, 51, 66 As doxycycline may also cause photosensitivity51,
patients should be counseled to wear extra sunscreen while traveling.

Mefloquine
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Mefloquine is indicated for the prophylaxis of malaria and the treatment of mild-tomoderate, uncomplicated, chloroquine-resistant P. vivax and uncomplicated P. falciparum

Pharmacologic//Pharmacokinetic Effects
Mefloquine is a quinoline-methanol compound structurally similar to quinine. Mefloquine acts as
a blood schizonticide but its exact mechanism of action is not known. It is a 4-aminoquinoline
with a fairly large volume of distribution, is highly protein bound and is primarily distributed in
the tissue.42, 67 With increased age, protein binding can potentially be affected. Healthy older
adults will have normal concentrations of important proteins like albumin and alpha-1-acid
glycoprotein which may be decreased by malnutrition and frailty.11 While mefloquine is a highly
protein bound drug, no changes in dosing based on weight or composition are currently
recommended.68
Mefloquine is primarily metabolized via CYP enzymes in the liver.69 Although the
natural decrease in liver function that occurs with aging will not usually affect mefloquine use,
caution should be taken in patients with liver disease.70 There are currently no dose adjustment
recommendations for hepatic impairment; however, the half-life is increased leading to
prolonged plasma levels.70 With increased drug exposure there is increased risk for adverse
effects including headache, gastrointestinal disturbances, nervousness, fatigue, disorders of sleep,
mood, memory and concentration, and occasionally psychosis.71
As only a small amount of mefloquine is renally eliminated, no major renal
considerations exist for the use of mefloquine.
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Pharmacodynamic Effects
Mefloquine may cause bradyarrhythmia, gastrointestinal issues, dizziness, headache,

side effects which include QT interval prolongation, seizures, suicidal ideations, and
pneumonitis.72

Drug-drug Interactions
As most drugs are hepatically metabolized, mefloquine does interact with other drugs that
rely on similar metabolism routes in the body. Both ketoconazole and ampicillin lead to higher
concentrations of mefloquine by decreasing its metabolism in the liver.67, 73 (Table 1)
Conversely, CYP enzyme inducers such as rifampin can lead to decreased mefloquine
concentrations.74 (Table 1) Ritonavir and mefloquine seem to interfere which each other’s
metabolism to varying extents but the clinical impact is unclear.75
Mefloquine can affect cardiac conduction, specifically slowing the heart rate and
increasing risk for QT prolongation.76, 77 Given this risk the WHO recommends caution when
using mefloquine with drugs that also affect cardiac conduction such as calcium channel
blockers, digoxin, amiodarone, quinolones, β-blockers, and other quinines.42 (Table 1)

Drug-disease interactions and Considerations in Older Adults
Neuropsychiatric
Mefloquine use is contraindicated in patients with epilepsy.78 Additionally, one of the
major concerns with mefloquine is the rare risk for neuropsychiatric adverse events including
anxiety, depression, mood changes, panic attacks, forgetfulness, confusion, hallucinations,
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aggression, psychotic or paranoid reactions.79 The CDC recommends avoiding use of mefloquine
in patients with pre-existing psychiatric disease or a strong family history of psychiatric

patients with first onset of a mood disorder at age 60 or older.81 There is no evidence to suggest
older adults are at higher risk of neuropsychiatric adverse events, however they should
appropriately be screened for mood disorders prior to use of mefloquine especially when used for
long term prophylaxis.
Cardiac
As the incidence of cardiovascular disease such as arrhythmias and the use of
antiarrhythmic drugs increases with age, older adults may be at a greater risk for cardiotoxicity
especially if taking mefloquine with a medication that affects cardiac conduction.82 Caution
should be exercised if prescribing mefloquine to ensure that drug-drug interactions, especially
those that affect cardiac conduction, are not present.

Primaquine
Primaquine is indicated for the prophylaxis of malaria and treatment, including radical
cure of Plasmodium vivax and P. ovale infections and presumptive anti-relapse therapy.

Pharmacologic/Pharmacokinetic Effects
Primaquine phosphate is an 8-aminoquinoline active against malaria parasites in the
erythrocytic, hepatic, and gamete phase of the plasmodium’s life cycle.83
Primaquine is broken down by monoamine oxidase into a predominant inactive
metabolite, carboxyprimaquine, which lacks efficacy and toxicity, as well as by CYP2C19,
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CYP2D6, and CYP3A4 enzymes into metabolites which are responsible for the antimalarial and
hemolytic toxicity of primaquine.84-86 The CYP2D6 enzyme may be essential for antimalarial

Once it is distributed in the body, primaquine is found in erythrocytes in high concentrations.
Primaquine is readily absorbed from the GI tract with 96% bioavailability.87 Primaquine and
carboxyprimaquine are primarily excreted through the biliary tract; however, some of
primaquine is also excreted unchanged in the urine.88 The elimination half-life is 4 to 7 hours and
no dosage adjustment is needed for renal insufficiency.89, 90 Although clinical studies have not
identified differences in response to treatment with primaquine in older adults versus younger
patients, the manufacturer recommends starting with low doses of this drug due to potential
physiologic changes in older adults.83

Pharmacodynamic Effects
Primaquine is usually well-tolerated. It may cause some GI discomfort which may be
dose-related.83 If this occurs, patients can take primaquine with food. Rarely, hypertension, QT
prolongation and cardiac arrhythmias occur.83

Drug-drug interactions
There are no clinically significant drug interactions resulting in toxicity with currently
marked drugs and primaquine. Quinine use may decrease the plasma concentration of
carboxyprimaquine, an inactive metabolite, by interfering with the production and elimination of
carboxyprimaquine.91 Dihydroartemisin-piperaquine and artesunate-pyronaridine may increase
the levels of primaquine and carboxyprimaquine by displacing bound primaquine and
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carboxyprimaquine from the tissues.85, 91 Chloroquine has also been shown to increase
primaquine geometric mean plasma concentration by 63%, which does not result in toxicity but

manufacturer of primaquine reports interactions with quinacrine and myeloid suppressive drugs.
(Table 1)83

Drug-disease Interactions and Considerations in Older Adults
G6PD deficiency
The most important adverse effect with primaquine is hemolysis which results when
patients are G6PD deficient. There are different variants of G6PD deficiency and these are
associated with different risks for hemolysis. In G6PD deficient people, hemolysis usually occurs
2 to 3 days after primaquine initiation. Both qualitative and quantitative point-of-care G6PD
testing is now available. The CDC states that quantitative G6PD deficiency testing must be done
prior to primaquine use.93 The severity of hemolysis depends on the dose, length of therapy, and
degree of G6PD deficiency. As primaquine is rapidly eliminated from the body, hemolysis stops
shortly after drug discontinuation. If primaquine must be used, it can be dose adjusted depending
upon the degree of G6PD deficiency.94 Hemolytic anemia, leukopenia, methemoglobinemia, and
granulocytopenia may also occur independently of G6PD deficiency.89
Rheumatoid arthritis and SLE
Primaquine use is contraindicated in acutely ill patients with granulocytopenia such as
patients with a severe subset of rheumatoid arthritis (RA) and SLE.95 This is an important
consideration especially in older adults who are more likely to suffer from RA than younger
individuals.95

Downloaded from https://academic.oup.com/jtm/advance-article-abstract/doi/10.1093/jtm/taz089/5644627 by Chapman University user on 06 December 2019

may have a synergistic effect.92 While no recent studies confirm these interactions, the

19
Other
Loss of efficacy has been observed in patients with poor and intermediate P450 CYP2D6

primaquine into active metabolites against hypnozoites in the liver.96

Drug Name: Tafenoquine
Arakoda® (US trade name) and Kodatef® (Australian trade name) are indicated for the
prophylaxis of malaria. Krintafel® (US trade name) and Kozenis® (Australian trade name) are
indicated for radical cure of P.vivax malaria.

Pharmacologic/Pharmacokinetic Effects
Similar to primaquine, tafenoquine is an 8-aminoquinoline.97, 98 It is active against all
stages of the parasite, including dormant liver stages of P.vivax and erythrocytic phase, having a
similar efficacy to mefloquine for prophylaxis.99
Unlike primaquine, tafenoquine is eliminated from the body at a much slower rate. The
terminal half-life of tafenoquine is 12-15 days, and co-administration with a high-fat meal
increases systemic exposure by 41%.94, 100 The longer half-life allows for weekly dosing where
primaquine must be dosed daily. Age does not appear to impact the pharmacokinetics of
tafenoquine.101, 102
Tafenoquine has not been studied in patients with renal and hepatic disease, however
renal and hepatic function should be monitored in patients with pre-existing disease.94
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activity phenotypes since isoenzyme 2D6 may be primarily responsible for metabolizing

20
Pharmacodynamic Effects
Gastrointestinal

as nausea, diarrhea, vomiting and motion sickness have occurred. If taken with food, the GI
adverse effects of tafenoquine may be minimized.
Hematologic
Moderate methemoglobinemia has been reported but is likely due to higher doses (>200
mg) daily or weekly.94 When used as a single dose, this adverse effect is very rare.94
Ophthalmic
Corneal deposits or epithelial keratopathy with prolonged use can occur with tafenoquine.
This was observed in 25% of individuals taking the drug for 6 months and it resolved within 1248 weeks upon discontinuation of the drug.94, 103
Other
Depression, photophobia, increased serum creatinine and serum alanine
aminotransferase, insomnia, and decreased hemoglobin have also been reported but with lesser
frequency.104

Drug-drug Interactions
Tafenoquine may increase the levels of multidrug and toxin extrusion (MATE1)
substrates and organic cation transporter (OCT2) substrates, which are renal transporters
important in renal elimination of drugs.105 If one or both renal transporters are inhibited as is the
case with tafenoquine, this can lead to toxicity of the substrates. Therefore, a combination of
tafenoquine with MATE1 or OCT2 substrates should be avoided. However, if the drugs must be
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The adverse effect profile of tafenoquine is like that of primaquine. GI disturbances such
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given together a dose reduction of MATE1 or OCT2 substrates should be considered to avoid
toxicity. Cisplatin, oxaliplatin, and metformin are a few examples of OCT2 and MATE2

likelihood for diabetes increases with age108, this may be an important consideration to take note
of since many patients with diabetes are often prescribed metformin for management of
diabetes.109 Tafenoquine has little effect on cytochrome P450 metabolized drugs like primaquine,
nor does it affect the pharmacokinetics of chloroquine when co-administered.110 Tafenoquine has
not been adequately studied in older adults.

Drug-disease interactions and Considerations in Older Adults
G6PD deficiency
As with primaquine, G6PD deficiency must be screened for prior to administration of
tafenoquine due to increased risk for hemolytic anemia.104 Females with a quantitative activity of
G6PD ≥30% to <70% are considered to be in the intermediate category, but because tafenoquine
has dose dependent hemolysis, males and females should have a quantitative test done to ensure
the activity is greater than 70% before it can be used for prophylaxis or treatment.94
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common genetic
disorder in humans.94 Since the G6PD gene lies on the X chromosome, males with a mutation on
the X chromosome and females with a mutation on both X chromosomes will have full
phenotypic expression of the deficiency.94 Females with a mixture of G6PD normal and G6PD
deficient red cells will have varying levels of G6PD deficiency.94 Qualitative testing for G6PD
deficiency is sufficient for males as they are either G6PD deficient or normal.94 However, for
females, a quantitative test must be done because of the possibility of having an intermediate
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substrates that have increased plasma levels when given with tafenoquine.105-107 (Table 1) As the
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level of G6PD deficiency.94 The threshold for normal G6PD qualitative test is ≥30%.94 Thus a
female heterozygous patient testing ―normal‖ may still have up to 70% of their red blood cells

that an older adult does not know their G6PD status.112
Hematologic
Methemoglobin elevations have been reported with tafenoquine use and this should be
considered prior to prescribing the medication, especially if used at higher doses.110
Neurologic
Tafenoquine should also be used with caution in patients with psychiatric disorders. With
higher doses of tafenoquine, serious psychiatric adverse events have been reported in patients
with a past medical history of psychiatric disorders.113 Anxiety, abnormal dreams, mood
changes, and trouble sleeping have been observed.104 These effects may have a delayed onset due
to longer half-life and longer time to Cmax of the drug.101 This is an especially important
consideration in older adults as data shows that the first onset of a mood disorder occurs at age
60 or older in 52% of patients.81 Patients with a history of psychotic disorders or current
psychotic symptoms, especially in deployed military personnel, should not use this drug.97, 114

Artemisinins Artesunate and Artemether
Artesunate is administered intravenously for the treatment of severe malaria and
Artemether with Lumefantrine (AL), with the trade name of Coartem® in US and Africa and
Riamet® in Europe, is used orally for treatment and standby emergency treatment of
uncomplicated malaria.
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G6PD deficient.111 As most patients with G6PD deficiency remain asymptomatic, it is possible
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Pharmacologic/Pharmacokinetic Effects
Both artemether and artesunate have similar pharmacodynamic properties as other

involve an iron-mediated cleavage of the endoperoxide bridge, which produces oxygen free
radicals, which then react with nearby molecules, interfering with parasite function.116 Both
artesunate and artemether are prodrugs that are rapidly hydrolyzed by plasma esterases to an
active metabolite, dihydroartemisinin (DHA), which then undergoes hepatic metabolism via
CYP2B6, CYP2C19, and CYP3A4 to inactive metabolites.117 Bodyweight has been linked to
differences in dosage necessary of artesunate, with children requiring higher dosages due to a
larger volume of distribution.42 No enhanced measures are recommended for older adults with
lower body weight. The exact mechanism of action of lumefantrine is unknown but it is thought
to prevent the formation of β-hematin by complexing with hemin, inhibiting nucleic acid and
protein synthesis, and eliminating residual parasites. While artemether clears most of the
parasitemia, lumefantrine concentrations that remain at the end of the 3- to 5-day course, due to
its long half-life of 3-6 days, are responsible for eliminating residual parasites.118 There is no
renal or hepatic dose modification necessary with the artemisinins, but they should be used
cautiously in severe impairment. A high-fat meal, as little as 1.2 g, can significantly increase the
AUC of lumefantrine, 5 fold, and artemether.119, 120

Pharmacodynamic Effects
Hypersensitivity reactions, some gastrointestinal disturbances, dizziness,
reticulocytopenia, and an increase in liver enzymes have been reported.42
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Drug-drug interactions
Similar to other antimalarials previously discussed, the artemesins and DHA, the active

life of intravenous artesunate, it is unlikely to incur clinically significant drug-drug
interactions.121 The drug-drug interactions with the best documentation are between AL and
ketoconazole and rifampin.122 Ketoconazole can increase levels of AL and DHA by CYP 3A4
inhibition 1.6 to 2.3 fold, leading to QT interval prolongation.120 Rifampicin, on the other hand,
is a CYP 3A4 enzyme inducer, thus, theoretically, leading to a decrease in AL plasma levels and
a potential decrease in antimalarial efficacy.123 The pharmacokinetic decrease of DHA with
ritonavir and similar drugs is thought to be due to the induction of uridine diphosphateglucuronosyltransferases (UGTs), the main route of elimination of DHA, by ritonavir. 124
Decreased exposure of DHA observed with ritonavir may negatively impact efficacy of
antimalarial therapy. Lumefantrine is also mainly metabolized by CYP3A4. Administration with
potent inducers of CYP3A4 may result in lower lumefantrine, artemether and DHA exposure and
potential failure of treatment. In clinical studies, artemether and DHA exposure were
substantially lower with concomitant use of nevirapine (NVP) and efavirenz (EFV).125, 126
Efavirenz, is a potent CYP 3A4 inducer and has shown to decrease the AUC of DHA by 50%,
potentially leading to AL treatment failure.127 Results with lumefantrine and NVP have been
mixed as NVP is a less potent inducer of CYP3A4 than EFV. In the South African and
Tanzanian studies, they found lumefantrine exposure increased at the end of a simulated 7-day
course, but a Ugandan study found a decrease in lumefantrine AUC.125, 126, 128 Speculation as to
the difference in effect on lumefantrine in the South African study is they provided a high fat
meal to participants and extended the regimen, which may be necessary to overcome this
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metabolite, interact with potent CYP 3A4 inducers and inhibitors as noted. With the short half-
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interaction with NVP.128 Conversely, when lumefantrine and the HIV drug lopinavir/ritonavir
were co-administered to HIV positive study participants, lumefantrine plasma concentrations

leads to better efficacy needs further study. A summary of drug-drug interactions and
artemisinins is listed in Table 1.

Drug-disease interactions and Considerations in Older Adults
Cardiac
While lumefantrine is structurally similar to halofantrine, which is known to cause
significant cardiotoxicity, pharmacologic modifications to the drug have borne out no increase in
QT prolongation.130, 131 The manufacturer, however, recommends against use in patients with
congenital QT prolongation and patients receiving other drugs known to affect the QT
interval.120 As mentioned previously, older adults may be at a greater risk for cardiotoxicity as
the incidence of cardiovascular disease such as arrhythmias and the use of antiarrhythmic drugs
increases with age.82

Chloroquine
Due to the high prevalence of chloroquine resistant P. falciparum malaria in most parts of
the world, chloroquine use has significantly declined over the years. Chloroquine is indicated for
malaria prophylaxis and treatment of susceptible plasmodium species. Hydroxychloroquine is
not commonly used for malaria prevention or treatment, but the adverse effect profile and drugdrug interactions are similar to chloroquine.
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were 10 times greater with no documented increase in adverse effects.129 Whether this interaction
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Pharmacologic/Pharmacokinetic Effects
Chloroquine is a 4-aminoquinoline and an anti-protozoal agent. While the exact

erythrocytes by the prevention of the polymerization of heme, leading to accumulation in the
parasite, which is toxic. Chloroquine is readily absorbed from the GI tract, and it is extensively
distributed in tissues such as liver, spleen, kidney, and lung.22 It is metabolized in the liver by
CYP2C8 and CYP3A4 enzymes, and about 55% of the medication is renally eliminated.19, 132, 133
There are currently no dosage adjustment recommendations for chloroquine. However, it
has been recommended to administer 50% of the chloroquine dose if the patient’s CrCl is less
than 10 mL/min.134

Pharmacodynamic Effects
Dermatologic
Pruritis can occur with chloroquine use and has a higher frequency in dark-skinned
individuals.135 Administration of an antihistamine at the same time as the administration of
chloroquine may help decrease the incidence of pruritis in susceptible individuals.136 However,
the American Geriatrics Society (AGS) 2019 Updated AGS Beers Criteria for Potentially
Inappropriate Medication Use in Older Adults states that first-generation antihistamines should
be avoided due to increased risk of adverse effects.15 Some examples of first-generation
antihistamines are brompheniramine, chlorpheniramine, diphenhydramine, doxylamine,
hydroxyzine, and meclizine.
Cardiac
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Although rare, QRS complex and QT interval prolongation along with cardiotoxicity
have been observed with chloroquine use.137 Older adults may be at a greater risk for

antiarrhythmic drugs increases with age.82
Other
Rarely, chloroquine may cause GI disturbances such as nausea, vomiting, and diarrhea,
hypoglycemia, hepatitis, elevated liver enzymes, and headache.138 Taking chloroquine with food
may help alleviate any GI adverse effects. Other adverse effects that may occur very seldom are
central nervous system changes, myopathy, photosensitivity, hearing loss, and blood disorders.138
If used chronically for long term prophylaxis, keratopathy and retinopathy may occur. For
indications other than acute malaria, the use of chloroquine is contraindicated in the presence of
retinal or visual field changes.139

Drug-drug Interactions
Chloroquine should be used cautiously with cimetidine, ampicillin, praziquantel,
thyroxine, cyclosporine, methotrexate, and antiepileptic medications due to drug interactions
using different mechanisms.140-146 (Table 1) It has been postulated that cimetidine may inhibit the
elimination of chloroquine and that chloroquine may decrease gastric emptying and gut motility
resulting in decreased ampicillin bioavailability.140, 141 The interaction between chloroquine and
praziquantel is not well understood, but it has been proposed that chloroquine may increase the
catabolism of thyroid hormones via enzymatic induction.143, 144 Chloroquine may increase
cyclosporine levels by inhibiting its metabolism through direct enzyme inhibition or by enzyme
competition.142, 147 Chloroquine may reduce the bioavailability of methotrexate when co-
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administered.146 Carbamazepine was reported to antagonize the effect of chloroquine.138
Chloroquine may also increase the risk for acute dystonic reactions when taken with

decrease the absorption of chloroquine.148, 149 (Table 1) Some medications (ie. antipsychotic
medications, cisapride, dronedarone, etc) are contraindicated with chloroquine due to the
increased risk for QT prolongation.138 (Table 1) Antidepressant medications such as citalopram,
escitalopram, fluoxetine, and some tricyclic antidepressants also pose a great risk for QT
prolongation with chloroquine.36 (Table 1)

Drug-disease interactions and Considerations in Older Adults
G6PD deficiency
Chloroquine may also cause hemolysis in glucose-6 phosphate dehydrogenase (G6PD)
deficient individuals and especially if these patients are taking medications which can also cause
hemolysis. These medications include dapsone, methylene blue, nitrofurantoin, phenazopyridine,
primaquine, rasburicase, and tolonium chloride.150 While it is not recommended to perform
G6PD testing, if the individual has the enzyme deficiency, it should not be used. Periodic checks
of complete blood cell counts are important if patients are taking chloroquine for an extended
period of time.
Cardiac
A scientific statement by the American Heart Association in 2016 concluded that
chloroquine might cause myocardial toxicity or exacerbate underlying myocardial dysfunction in
cases of long-term use and with high doses.137 Older adults, female sex, long duration of therapy
(3 months – 27 years; mean > 10 years), high doses, preexisting cardiac disease, and renal
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insufficiency are all risk factors for cardiotoxicity.137, 151, 152 Drug-drug interaction should always
be checked with chloroquine especially in older adults to ensure that the risk for QT prolongation

Hypoglycemia
Hypoglycemia has been reported with chloroquine. As older adults are at a higher risk for
hypoglycemia during treatment for diabetes with glucose lowering medications, close monitoring
of blood sugars is warranted if chloroquine is used for malaria prevention or treatment.18
Ophthalmic
The risk of retinopathy is also increased if a patient has decreased renal function or is
taking tamoxifen.153, 154 Older adults should have normal renal function when taking chloroquine
as these individuals are more prone to renal impairment.12 Age, however, does not seem to
correlate to retinal toxicity.154 The American Academy of Ophthalmology (AAO) recommends
baseline screening for retinal toxicity and annual screening for patients taking chloroquine for
longer than 5 years as the risk of retinal toxicity increases from less than 1% over 5 years to 2%
up to 10 years, and to 20% after 20 years.153
Other
Chloroquine may exacerbate psoriasis, neurological, retinal, or gastrointestinal
disorders.138 Exacerbation and, rarely, induction of plaque-type psoriasis can occur, typically
after 4 to 12 weeks of use, but the actual risk is unknown.155 Chloroquine should be used with
caution in patients with hepatic impairment as it may accumulate in the liver, thereby resulting in
hepatic toxicity. This is an important consideration in older adults as they are more likely to have
multiple co-morbid conditions, including decreased hepatic function.12, 66
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As older adults may have more comorbid conditions such as diabetes mellitus, heart
disease, and retinopathy, the risk for hypoglycemia, cardiotoxicity, QT interval prolongation, and

individuals.108, 156 This is especially true if an older adult requires long term malaria prophylaxis.

Limitations
Limited data was found on drug-drug interactions in older patients once the literature
search was performed. The limited data and lack of recent literature prevented the authors from
performing a systematic review or meta-analysis due to the lack of heterogeneity in the evidence.

Conclusion
While the proportion of older adults traveling to malarious areas is small compared to
younger groups, special attention is warranted due to their unique changes in physiology and
how drugs are affected by their pharmacokinetic parameters. In addition, older adults are more
likely to take multiple medications and have chronic medical conditions. As a result, older adults
may be at a higher risk for drug-drug and drug-disease interactions such as cardiotoxicity or over
anticoagulation. With some exceptions, older adults are not more likely to experience adverse
effects or decreased efficacy due to drug-drug interactions any differently than younger groups.
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Table 1. Summary of Antimalarial Drug-Drug Interactions
Generic
Drug Name

High Risk Interacting
Drugs

Quality of
Documentation/Reco
mmended actionⱡ

Drug-Drug Considerations
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46
Mefloquine

QT prolongation
drugs

Quality of
documentation varies
based on
drug/Contraindicated
or use with extreme
caution



Caution with drugs that
affect cardiac conduction
(B-blocker, digoxin,
amiodarone, etc.) due to
QT prolongation



Rifampin





Ketoconazole

Good/Avoid
concurrent use
Good/Contraindicate
d



Cyclosporine (↑)

Good/Avoid
concurrent use



Decreased exposure with
concurrent rifampin
Increased exposure with
concurrent ketoconazole
and increased risk for
cardiotoxicity
Monitor cyclosporine
levels for toxicity



Tamoxifen





QT prolongation
drugs

Fair/Avoid
concurrent use
Quality of
documentation varies
based on
drug/Contraindicated
or use with extreme
caution



Cimetidine (↑)

Good/Avoid
concurrent use





Carbamazepine
(↓)
Praziquantel (↓)
Thyroxine (↓)

Fair/Avoid
concurrent use
Good/Precaution















Antacids

Good/Avoid
concurrent use



Increased risk for
retinopathy
Augmentation of QT
prolongation effect (ie.
some antidepressants,
antiarrhythmics, certain
antipsychotics, some
HIV medications, certain
antiemetics, etc.)
Suggest switching to
another anti-ulcer
medication with less
potential to alter the
pharmacokinetics of
chloroquine

Decreased bioavailability
of these agents
Consider dose increase of
praziquantel is patient is
not responding to
treatment
Monitor TSH levels
when starting and
discontinuing
chloroquine therapy
Reduced absorption with
antacids
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Chloroquine



47





Antacids
Bismuth
subsalicylate
Oral iron

Good/Avoid
concurrent use









Rifampin

Good/Avoid
concurrent use








Carbamazepine
Phenytoin
Phenobarbital
Warfarin (↑)

Fair/Avoid
concurrent use



Fair/Precaution





Methotrexate (↑)

Good/Use with
caution



Primaquine



Quinacrine

Contraindicated (PI)



Atovaquoneproguanil



Ritonavir,
efavirenz,
rifamycins
Tetracycline

Good/Use not
recommended



Good/Use not
recommended
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Doxycycline

Administration should be
separated by at least four
hours
Doxycycline should be
taken at least one to two
hours before aluminum,
calcium or magnesium
containing products
Doxycycline should be
taken at least two to three
hours before the bismuth
subsalicylate dose
Iron salts should be given
not less than three hours
before or two hours after
the doxycycline dose
May decrease plasma
concentration of
doxycycline
May decrease plasma
concentration of
doxycycline
Closely monitor INR at
initiation and withdrawal
of doxycycline therapy
and reassess periodically
during concurrent
therapy
Closely monitor for
evidence of methotrexate
toxicity especially at high
methotrexate doses;
consider an alternative to
doxycycline
Manufacturer
recommendation (may
increase toxicity of
primaquine)
Decreased plasma
concentration of
atovaquone/proguanil
Decreased plasma
concentration of
atovaquone/proguanil

48
Metoclopramide



Warfarin (↑)





Cisplatin
Metformin
Oxaliplatin

Fair/Use with caution
only if other options
not available
Good/Precaution



Decreased bioavailability
of atovaquone/proguanil



Fair/
Precaution



Closely monitor INR at
initiation and withdrawal
of antimalarial therapy
Increases levels of
multidrug and toxin
extrusion (MATE1)
substrates and organic
cation transporter 2
(OCT2) substrates
Avoid with potent CYP
3A4 inducers or
inhibitors
Augmentation of QT
prolongation effect
Caution with potent CYP
3A4 inducers or
inhibitors

Excellent/Contraindic

Rifampin ()
ated
Ketoconazole
()

 QT prolongation
drugs
Fair/Precaution
 Darunavir,

ritonavir,
lopinavir,
ritonavir,
nevirapine,
efavirenz,
etravirine
±
Classification and strength of evidence adapted from Micromedex Online Solutions.
Greenwood Village, CO: Truven Health Analytics. http://micromedex.com/. Accessed date
August 2019

Artemisinins
(Artesunate,
Artemether/L
umefantrine)
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